Search Results - "Vadakekolathu, J."

Membrane Hsp70 as a biomarker for aggressive prostate cancer and therapeutic target by Foulds, G.A, Dunning-Foreman, N, Stangl, S, Gehrmann, M, Vadakekolathu, J, Boocock, D, Rees, R, Multhoff, G, Pockley, A.G

Get full text

P1426: WU‐NK‐101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) by Muth, J. J., Mathyer, M. E., Cruz, B., DuFour, C., Leedom, T., Hamil, A. S., Pouyanfard, S., Berrien‐Elliot, M., Luukkonen, L., Tran, M., Tumala, B., Pomper, N., Arthur, L., Foster, M., Gorrochategui, J., Comune Pennacchi, P., Primo, D., Ballesteros, J., Tolstikov, V., Kiebish, M. A., Shah, P., Vadakekolathu, J., Rutella, S., Fehniger, T. A., Sullivan, R., Kabakibi, A., Cooper, M. L., Davidson‐Moncada, J.

Get full text

Novel PAP-derived vaccine for the treatment of advanced prostate cancer by Le Vu, P., Vadakekolathu, J., Nicholls, H., Christensen, D., Durrant, L., Pockley, A., McArdle, S.E.

Get full text

648 - Membrane Hsp70 as a biomarker for aggressive prostate cancer and therapeutic target by Foulds, G.A., Dunning-Foreman, N., Stangl, S., Gehrmann, M., Vadakekolathu, J., Boocock, D., Rees, R., Multhoff, G., Pockley, A.G.

Get full text

123PEvaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA) by Rutella, S, Church, S E, Vadakekolathu, J, Reeder, S, Sullivan, A H, Warren, S, Baughman, J, Muth, J, Park, H, Uronis, H, Kang, Y -K, Ng, M C H, Enzinger, P, Lee, K W, Huber, K, Wynter-Horton, A, Li, D, Bang, Y-J, Davidson-Moncada, J, Catenacci, D V

“…Abstract Background Despite improvements in treatments, the 5-year survival of GEA patients (pts) is disappointing. Individual molecular subtypes display…”
Get full text

1189PD - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T) by Park, H., Uronis, H., Kang, Y.-K., Ng, M.C.H., Enzinger, P., Lee, K.W., Rutella, S., Church, S.E., Nordstrom, J., Knutson, K., Erskine, C., Wu, T., Yen, J., Franovic, A., Muth, J., Rosales, M., Vadakekolathu, J., Davidson-Moncada, J., Bang, Y.-J., Catenacci, D.V.

“…T + chemo is standard 1st line therapy for HER2+ gastroesophageal adenocarcinoma; however, patients (pts) tend to progress in 6-8 months. Up to 40% show loss…”
Get full text

Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T) by Park, H., Uronis, H., Kang, Y.-K., Ng, M.C.H., Enzinger, P., Lee, K.W., Rutella, S., Church, S.E., Nordstrom, J., Knutson, K., Erskine, C., Wu, T., Yen, J., Franovic, A., Muth, J., Rosales, M., Vadakekolathu, J., Davidson-Moncada, J., Bang, Y.-J., Catenacci, D.V.

Get full text

123P - Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA) by Rutella, S., Church, S.E., Vadakekolathu, J., Reeder, S., Sullivan, A.H., Warren, S., Baughman, J., Muth, J., Park, H., Uronis, H., Kang, Y.-K., Ng, M.C.H., Enzinger, P., Lee, K.W., Huber, K., Wynter-Horton, A., Li, D., Bang, Y.-J., Davidson-Moncada, J., Catenacci, D.V.

“…Despite improvements in treatments, the 5-year survival of GEA patients (pts) is disappointing. Individual molecular subtypes display preferential responses to…”
Get full text

1189PDDeterminants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T) by Park, H, Uronis, H, Kang, Y-K, Ng, M C H, Enzinger, P, Lee, K W, Rutella, S, Church, S E, Nordstrom, J, Knutson, K, Erskine, C, Wu, T, Yen, J, Franovic, A, Muth, J, Rosales, M, Vadakekolathu, J, Davidson-Moncada, J, Bang, Y-J, Catenacci, D V

“…Abstract Background T + chemo is standard 1st line therapy for HER2+ gastroesophageal adenocarcinoma; however, patients (pts) tend to progress in 6-8 months…”
Get full text

PF401 IMMUNE SYSTEM AND CHRONIC MYELOID LEUKEMIA: THE IMPACT OF TYROSINE KINASE INHIBITORS by Alves, R.S., McArdle, S.E., Vadakekolathu, J., Gonçalves, A.C., Freitas‐Tavares, P., Pereira, A., Almeida, A.M., Sarmento‐Ribeiro, A.B., Rutella, S.

“…Background: During carcinogenesis, tumor cells alter their immunogenicity in an attempt to escape surveillance of the immune system (SI). This surveillance…”
Get full text

Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA) by Rutella, S., Church, S.E., Vadakekolathu, J., Reeder, S., Sullivan, A.H., Warren, S., Baughman, J., Muth, J., Park, H., Uronis, H., Kang, Y.-K., Ng, M.C.H., Enzinger, P., Lee, K.W., Huber, K., Wynter-Horton, A., Li, D., Bang, Y.-J., Davidson-Moncada, J., Catenacci, D.V.

Get full text